title: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
abstract: BACKGROUND
  Perioperative cisplatin-based chemotherapy has shown benefit in patients with high-risk localized urothelial bladder cancer, but it is not widely used. Renal impairment may be a major factor limiting its use. The current study was designed to determine the proportion of patients ineligible to receive adjuvant cisplatin-based chemotherapy based on inadequate renal function alone.
  
  
  METHODS
  Patients who underwent radical cystectomy for urothelial cancer of the bladder with evidence of extravesical disease (> or =pT3 or any N+) were identified. Patients who received neoadjuvant chemotherapy were excluded. Serum creatinine immediately before and nadir serum creatinine after cystectomy were used to calculate creatinine clearance (CrCl) or glomerular filtration rate (GFR) using the Cockroft-Gault (CG), Jelliffe, and Modification of Diet in Renal Disease (MDRD) study formulas. A cutoff of CrCl <60 mL/min or GFR <60 mL/min/1.73 m2 was used to determine ineligibility for cisplatin-based chemotherapy. The proportion of patients ineligible by each formula was compared by univariate logistic regression. Univariate linear regression was performed to determine the effect of age on CrCl or GFR.
  
  
  RESULTS
  : Most patients were pT3 or greater; 39% were lymph node-positive. The overall proportion of patients ineligible for cisplatin-based chemotherapy was 28% by the CG formula, 52% by Jelliffe, and 24% by MDRD. Concordance between formulas was low. With all formulas the probability of ineligibility increased with age: by the CG equation, >40% of patients age >70 years were ineligible.
  
  
  CONCLUSIONS
  : The widespread use of cisplatin-based perioperative chemotherapy in patients with high-risk localized bladder cancer may be significantly limited by the high prevalence of baseline renal insufficiency in this population. This finding is most striking in the elderly. Better selection of patients who may safely receive cisplatin and more effective regimens devoid of cisplatin are required to optimize outcomes in this group of patients.
authors.affiliation: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: Atreya
authors.initials: A
authors.lastname: Dash
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Vickers
authors.forename: Angel M
authors.initials: AM
authors.lastname: Serio
authors.forename: Theresa M
authors.initials: TM
authors.lastname: Koppie
authors.forename: Guido
authors.initials: G
authors.lastname: Dalbagni
authors.forename: Bernard H
authors.initials: BH
authors.lastname: Bochner
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage*; D015653:Cystectomy; D004608:Eligibility Determination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D051437:Renal Insufficiency / Q000150:complications*; D012189:Retrospective Studies; D014523:Urethral Neoplasms / Q000150:complications / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000601:surgery
chemical_list: D002945:Cisplatin